Fertility and its complications in a patient with salt losing congenital adrenal hyperplasia.
A report is made concerning fertility and its complications in a patient with salt losing congenital adrenal hyperplasia. Fertility with a successful outcome of pregnancy has rarely been reported in women with salt losing congenital adrenal hyperplasia. Problems which have been identified in the past include non-compliance, poor endocrine follow up, secondary polycystic ovarian disease with menstrual irregularity, anovulation and problems related to sexual function. There has been only one report in the literature of a woman with salt losing congenital adrenal hyperplasia who has had two pregnancies with live births. There has been no previous report of subsequent problems with neonatal management of these children. This case highlights some of the long term hazards of management of salt losing congenital adrenal hyperplasia and reports for the first time neonatal complications possibly consequent upon prenatal maternal therapy.
Department of Endocrinology and Diabetes, Royal Children's Hospital, Parkville, Victoria, Australia.
M
M
Zacharin
D019326:17-alpha-Hydroxyprogesterone / Q000097:blood; D000311:Adrenal Glands / Q000187:drug effects; D000312:Adrenal Hyperplasia, Congenital / Q000097:blood / Q000188:drug therapy*; D000328:Adult; D000735:Androstenedione / Q000097:blood; D005260:Female; D005438:Fludrocortisone / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D006854:Hydrocortisone / Q000009:adverse effects / Q000627:therapeutic use; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000139:chemically induced; D011247:Pregnancy; D011248:Pregnancy Complications / Q000209:etiology*; D011297:Prenatal Exposure Delayed Effects
D000735:Androstenedione; D019326:17-alpha-Hydroxyprogesterone; D005438:Fludrocortisone; D006854:Hydrocortisone